Clinical Trial Update: Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) [NA]

View source ↗

Summary

Clinical trial update for DZD9008, an oral EGFR inhibitor, in patients with advanced non-small cell lung cancer with EGFR mutations. The study is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DZD9008

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Non Small Cell Lung Cancer | NA | Status: RECRUITING